Effects of adjuvants on the immune response to allergens in a murine model of allergen inhalation: Cholera toxin induces a Th1-like response to Bet v 1, the major birch pollen allergen

Clinical and Experimental Immunology

Volumn 111, Issue 1, 1998, Pages 144-151

  Wiedermann, U ^a   Jahn Schmid, B ^a,b   Fritsch, R ^a   Bauer, L ^a   Renz, H ^c   Kraft, D ^a   Ebner, C ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Adjuvant; Aerosol; Allergy; BALB c; Mucosal; Th1; Th2

Indexed keywords

ALLERGEN; ALUMINUM HYDROXIDE; CHOLERA TOXIN; CONCANAVALIN A; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 4; POLLEN ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; FEMALE; HELPER CELL; IMMUNE RESPONSE; IMMUNIZATION; INHALATION; LUNG LAVAGE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN MANIFESTATION; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INHALATION; ALLERGENS; ANIMALS; CHOLERA TOXIN; FEMALE; HYPERSENSITIVITY; MICE; MICE, INBRED BALB C; PLANT PROTEINS; POLLEN; TH1 CELLS;

EID: 0031929609     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1998.00477.x     Document Type: Article

References (55)

1. Wuethrich B, Schindler C, Leuenberger P, Ackermann-Liebrich U. Prevalence of atopy and pollinosis in the adult population of Switzerland (Sapaldia study). Int Arch Allergy Immunol 1995; 106:149-56.
2. Ipsen H, Loewenstein H. Isolation and characterization of the major allergen of birch pollen (Betula verrucosa). J Allergy Clin Immunol 1983; 72:150-9.
3. Jarolim E, Rumpold H, Endler AT, Ebner H, Scheiner O, Kraft D, IgE and IgG antibodies of patients with allergy to birch pollen as tools to define the allergen profile of Betula verrucosa. Allergy 1989; 44:385-95.
4. Ebner C, Szepfalusi Z, Ferreira F et al. Identification of multiple T cell epitopes on Bet v 1, the major birch pollen allergen, using specific T cell clones and overlapping peptides. J Immunol 1993; 150:1047-52.
5. Ebner C, Schenk S, Najafian N et al. Nonallergic individuals recognize the same T cell epitopes of Bet v 1, the major birch pollen allergen, as atopic patients. J Immunol 1995; 154:1932-40.
6. Bauer L, Bohle B, Jahn-Schmid B, Wiedermann U, Daser A, Renz H, Kraft D, Ebner C. Modulation of the allergic immune response in BALB/c mice by subcutaneous injection of high doses of the dominant epitope from the major birch pollen allergen Bet v 1. Clin Exp Immunol 1997; 107:536-41.
7. Mossmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Ann Rev Immunol 1989; 7:145-73.
8. Maggi E, Del Prete GF, Macchia D, Parronchi P, Tiri A, Chretien I, Ricci M, Romagnani S. Profiles of lymphokine activities and helper function for IgE in human T cell clones. Eur J Immunol 1988; 18:1045-50.
9. Pène J, Rousset F, Brière F, Chrètien I, Paliard X, Banchereau H, Spits H, de Vries JE. IgE production by normal B cells induced by alloreactive T cell clones is mediated by IL-4 and suppressed by IFN-γ. J Immunol 1988; 141:1218-24.
10. Umetsu DT, Jabara HH, de Kruyff RH, Abbas AK, Abrams JS, Geha RF. Functional heterogeneity among human inducer T cell clones. J Immunol 1988; 140:4211-6.
11. + T cells from allergic individuals. J Exp Med 1993; 178:2123-30.
12. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Mueller UR. Bee venom immunotherapy results in decrease of IL-5 and IL-6 and increase of IFN-γ secretion in specific allergen stimulated T cell cultures. J Immunol 1995; 154:4187-94.
13. + T lymphocytes and eosinophils in the basal mucosa and increases in the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996; 97:1356-65.
14. Ebner C, Siemann U, Bohle B et al. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from Th2 to Th1 in T cell clones specific for Ph1 pl, a major grass pollen allergen. Clin Exp Allergy 1997; 27:1007-15.
15. Norman PS, Ohman JL, Long AA et al. Treatment of cat allergy with T cell reactive peptides. Am J Respir Crit Care Med 1996; 154:1623-8.
16. Ferreira F, Hirtenlehner K, Jilek A et al. Dissection of immunoglobulin E and T cell reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy. J Exp Med 1996; 183:599-609.
17. Ishizaka K. Regulation of IgE synthesis. Ann Rev Immunol 1984; 2:159-82.
18. Freund J. The mode of action of immunologic adjuvants. Adv Tuberc Res 1956; 7:130-51.
19. Jahn-Schmid B, Graninger M, Glozik M, Küpcü S, Ebner C, Unger FM, Sleytr U, Messner P. Immunoreactivity of allergen (Bet v 1) conjugated to crystalline bacterial cell surface layer (S-layers). Immunotechnology 1996; 2:103-13.
20. Elson CO, Eadling W. Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J Immunol 1984; 132:2736-41.
21. Pierce NF, Gowans JL. Cellular kinetics of the intestinal immune response to cholera toxoid in rats. J Exp Med 1975; 142:1550-63.
22. Xu-Amano J, Jackson RJ, Staats HF et al. Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J Exp Med 1993; 178:1309-20.
23. Snider D, Marshall J, Perdue M, Liang H. Production of IgE antibody and allergic sensitization of intestinal and peripheral tissues after oral immunization with protein ag and cholera toxin. J Immunol 1994; 153:647-57.
24. Tamura S, Shoji Y, Hasiguchi K, Aizawa C, Kurata T. Effects of cholera toxin adjuvant on IgE antibody response to orally or nasally administered ovalbumin. Vaccine 1994; 12:1238-40.
25. Bromanda AK, Kjerrulf M, Holmgren J, Lycke N. Cholera toxin enhances alloantigen presentation by cultured intestinal epithelial cells. Scand J Immunol 1993; 37:452-8.
26. Marinaro M, Staats HF, Hiroi T et al. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J Immunol 1995; 155:4621-9.
27. Wilson AD, Bailey M, Williams NA, Stokes CR. The in vitro production of cytokines by mucosal lymphocytes immunized by oral administration of keyhole limpet hemocyanin using cholera toxin as an adjuvant. Eur J Immunol 1991; 21:2333-9.
28. Vajdy M, Lycke N. Stimulation of antigen specific T and B cell memory in local as well as systemic lymphoid tissues following oral immunization with cholera toxin adjuvant. Immunology 1993; 80:197-203.
29. Reuman P, Keeley SP, Schiff GM. Similar subclass antibody responses after intranasal immunization with UV-inactivated RSV mixed with cholera toxin or live RSV. J Med Virol 1991; 35:192-7.
30. Ebner C, Birkner T, Valenta R, Rumpold H, Breitenbach M, Scheiner O, Kraft D. Common epitopes of birch pollen and apples - studies by Western and Northern blots. J Allergy Clin Immunol 1991; 88:588-94.
31. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-54.
32. Renz H, Smith HR, Henson JE, Ray BS, Irvin C, Gelfand E. Aerosolized antigen exposure without adjuvant causes increased IgE production and increased airway responsiveness in the mouse. J Allergy Clin Immunol 1991; 89:1127-38.
33. Malling HJ, Weeke B. Position paper: immunotherapy. Allergy 1993; 48 (14 Suppl.):7-35.
34. Holt PG, Batty JE, Turner KG. Inhibition of specific IgE responses in mice by pie-exposure to inhaled antigen. Immunology 1981; 42:409-17.
35. + T cell dependent immune deviation resulting in selective suppression of immunoglobulin E production. J Exp Med 1993; 178:889-99.
36. Renz H, Saloga J, Bradley KL, Loader JE, Greenstein JL, Larsen G, Gelfand EW. Specific Vβ T cell subsets mediate the immediate hypersensitivity response to ragweed allergen. J Immunol 1993; 151:1907-17.
37. Tada T. Regulation of reaginic antibody formation in experimental animals. Prog Allergy 1975; 19:122-94.
38. Scicchitano R, Husband AD, Clancy RL. Contribution of intraperitoneal immunization to the local immune response in the respiratory tract of sheep. Immunology 1984; 53:375-84.
39. Kuper CF, Koornstra PJ, Hameleers D, Biewenga J, Spit B, Duijvestijn A, Vriesman P, Sminia T. The role of the nasopharyngeal lymphoid tissue. Immunol Today 1992; 13:219-24.
40. Lycke N, Holmgren J, Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology 1986; 59:301-8.
41. Bourguin I, Chardes T, Bout D. Oral immunization with Toxoplasma gondii antigens in association with cholera toxin induces enhanced protective and cell mediated immunity in C57B1/6 mice. Infect Immun 1993; 61:2082-8.
42. Snapper CM, Paul WE. Interferon gamma and B cell stimulatory factor I reciprocally regulate Ig isotype production. Science 1987; 236:944-7.
43. Coleman JW, Buckley MG, Holliday MR, Morris AG. Interferon γ inhibits serotonin release from mouse peritoneal mast cells. Eur J Immunol 1991; 2:2559-64.
44. O'Hehir RE, Garman RD, Greenstein JL, Lamb JR. The specificity and regulation of T cell responsiveness to allergens. Annu Rev Immunol 1991; 9:67-95.
45. Yamamoto M, Vancott JL, Okahashi N et al. The role of Th1 and Th2 cells for mucosal IgA responses. Ann NY Acad Sci 1996; 778:64-71.
46. Creticos PS, Franklin-Adkinson HJ, Krager-Sobotka A. Nasal challenge with ragweed in hayfever patients: effect of immunotherapy. J Clin Invest 1985; 76:2247-53.
47. Varney VA, Hamid QA, Gaga M. Usefulness of immunotherapy in patients with severe summer hay fever incontrolled by anti-allergic drugs. BMJ 1991; 303:265-9.
48. Bousquet J, Becker WM, Hejjaoui I. Differences in clinical and immunological reactivity of patients allergic to grass pollen and to multiple-pollen species. II. Efficacy of a double blind placebo controlled, specific immunotherapy with standardized extracts. J Allergy Clin Immunol 1991; 88:43-53.
49. Audera C, Ramirez J, Soler E, Carreira J. Liposomes as carrier for allergy immunotherapy. Clin Exp Allergy 1991; 21:139-44.
50. Dean T. Liposomes in allergy and immunology. Clin Exp Allergy 1993; 23:557-63.
51. Giovane AL, Bardare M, Passalacqua G, Ruffoni S, Scordamaglia A, Ghezzi E, Canonica GW. A three year double blind placebo controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in pediatric patients. Clin Exp Allergy 1994; 24:53-59.
52. Sabbah A, Hassoun S, Le-Sellin J, Andre C, Sicard H. A double blind, placebo controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy 1994; 49:309-13.
53. Hirabayashi Y, Kurata H, Funato H, Nagamine T, Aizawa C, Tamura S, Shimada K, Kurate T. Comparison of intranasal inoculation of influenza HA vaccine combined with cholera B subunit with oral or parenteral vaccination. Vaccine 1990; 8:243-8.
54. Douce G, Tucotte C, Cropley I, Roberts M, Pizza M, Domenghini M, Rappuoli R, Dougan G. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc Natl Acad Sci USA 1995; 92:1644-8.
55. Roberts M, Bacon A, Rappuoli R et al. A mutant Pertussis toxin molecule that lacks ADP-ribosyltransferase activity. PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins. Infect Immun 1995; 63:2100-8.